Short answer
Alector, Inc. (ALEC) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $163M (up 4895.9% year over year) with net income of $125M.
Q3 2026 key financials · XBRL
- Revenue
- $163M
- +4895.9% YoY · +4805.6% QoQ
- Net income
- $125M
- +459.4% YoY · +642.0% QoQ
- Operating margin
- 76.0%
- EPS (diluted)
- $1.11
- +426.5% YoY · +655.0% QoQ
Source: XBRL data from the Alector, Inc. (ALEC) Q3 2026 10-Q on SEC EDGAR. USD.
Alector, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $162.9M, up $159.6M YoY from $3.3M, driven by GSK deferred-revenue recognition
- Net income $124.6M vs net loss $34.7M YoY, operating margin 76.0% vs negative 1,153.4%
- AL137/AL037 R&D $3.5M, other programs $18.5M, strongest disclosed development spending
- Cash, equivalents and marketable securities $138.7M; operating cash outflow $108.2M for nine months
- Genentech $100.0M upfront and October offering $75.0M gross; funding expected into second half of 2029
Risk Factors
- Newly added financing risk: October 2026 underwritten offering and Genentech upfront payment expected to extend cash runway into the second half of 2029
- Most material update, regulatory operations: FDA staffing reductions and policy changes may delay submissions, inspections, and clinical development timelines
- Clinical risk: GSK discontinued PROGRESS-AD in April 2026 after interim futility analysis found nivisnebart unlikely to meet its primary endpoint
- Competitive risk: Approved Alzheimer’s therapies lecanemab and donanemab may hinder enrollment and intensify market competition
- Financial concentration risk: Future Genentech revenue depends on AL050 milestones, royalties, and product sales that may never occur
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Alector, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.